Trials / Recruiting
RecruitingNCT06751589
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Pilot Weight Loss Intervention With Dual GIP/GLP-1 Receptor Agonist Therapy in Patients With Endometrial Cancer and Obesity, Overweight, With or Without Diabetes
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | 2.5 mg administered using a pre-filled injector once weekly for 4 weeks and then increase to 5 mg once weekly. |
Timeline
- Start date
- 2024-12-19
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2024-12-30
- Last updated
- 2026-04-13
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06751589. Inclusion in this directory is not an endorsement.